Back to Authors

Repka, Michael X.

https://orcid.org/0000-0002-0192-6951

Mayo Clinic

Johns Hopkins University

Citations 18

Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity
Crouch, Eric R. , Kraker, Raymond T. , Wallace, David K. , Holmes, Jonathan M. , Repka, Michael X. , Collinge, Janine E., Bremer, Don L., Gray, Michael E. , Smith, Heather , Steinkuller, Paul G., Holmes, Jonathan M.

JAMA Ophthalmology | November 7, 2019 | Volume: 138 | Issue: 1 | Pages: 14

10.1001/jamaophthalmol.2019.4488 Get It

Visual Acuity and Ophthalmic Outcomes in the Year After Cataract Surgery Among Children Younger Than 13 Years
Repka, Michael X. , Dean, Trevano W., Kraker, Raymond T. , Bothun, Erick D. , Morrison, David G., Lambert, Scott R. , Stahl, Erin D., Wallace, David K. , Herlihy, Erin P.

JAMA Ophthalmology | May 16, 2019 | Volume: 137 | Issue: 7 | Pages: 817

10.1001/jamaophthalmol.2019.1220 Get It

Atropine vs Patching—Reply
Repka, Michael X. , Kraker, Raymond T. , Holmes, Jonathan M. , Holmes, Jonathan M.

JAMA Ophthalmology | February 19, 2015 | Volume: 133 | Issue: 5 | Pages: 619

10.1001/jamaophthalmol.2014.6131 Get It

Atropine vs Patching for Treatment of Moderate Amblyopia
Repka, Michael X. , Kraker, Raymond T. , Holmes, Jonathan M. , Summers, Allison I. , Glaser, Stephen R., Barnhardt, Carmen, Tien, David Robbins, Kulp, Marjean Taylor , Felius, Joost , Holmes, Jonathan M.

JAMA Ophthalmology | May 1, 2014 | Volume: 132 | Issue: 7 | Pages: 799

10.1001/jamaophthalmol.2014.392 Get It

Feasibility of a Clinical Trial of Vision Therapy for Treatment of Amblyopia
Lyon, Don, Hopkins, Kristine B., Chu, Raymond, Tamkins, Susanna M. , Melia, B. Michele, Holmes, Jonathan M. , Repka, Michael X. , Wheeler, David T., Sala, Nicholas A., Dumas, Janette, Silbert, David I., Group, the Pediatric Eye Disease Investigator, Kulp, Marjean Taylor , Cotter, Susan A. , Group, the Pediatric Eye Disease Investigator, Holmes, Jonathan M.

Optometry and Vision Science | April 5, 2013 | Volume: 90 | Issue: 5 | Pages: 475-481

10.1097/opx.0b013e31828def04 Get It

ABSTRACT Purpose We conducted a pilot randomized clinical trial of office‐based active vision therapy for the treatment of childhood amblyopia to determine the feasibility of conducting a full‐scale randomized clinical trial. Methods A training and certification program and manual of procedures were developed to certify therapists to administer a standardized vision therapy program in ophthalmology and optometry offices consisting of weekly visits for 16 weeks. Nineteen children, aged 7 to less than 13 years, with amblyopia (20/40–20/100) were randomly assigned to receive either 2 hours of daily patching with active vision therapy or 2 hours of daily patching with placebo vision therapy. Results Therapists in diverse practice settings were successfully trained and certified to perform standardized vision therapy in strict adherence with protocol. Subjects completed 85% of required weekly in‐office vision therapy visits. Eligibility criteria based on age, visual acuity, and stereoacuity, designed to identify children able to complete a standardized vision therapy program and judged likely to benefit from this treatment, led to a high proportion of screened subjects being judged ineligible, resulting in insufficient recruitment. There were difficulties in retrieving adherence data for the computerized home therapy procedures. Conclusions This study demonstrated that a 16‐week treatment trial of vision therapy was feasible with respect to maintaining protocol adherence; however, recruitment under the proposed eligibility criteria, necessitated by the standardized approach to vision therapy, was not successful. A randomized clinical trial of in‐office vision therapy for the treatment of amblyopia would require broadening of the eligibility criteria and improved methods to gather objective data regarding the home therapy. A more flexible approach that customizes vision therapy based on subject age, visual acuity, and stereopsis might be required to allow enrollment of a broader group of subjects.
The Pediatric Eye Disease Investigator Group Report May Be Too Optimistic About Efficacy of Treatment: In Reply
Repka, Michael X. , Group, on Behalf of Pediatric Eye Disease Investigator, Quinn, Graham E. , Beck, Roy W. , Holmes, Jonathan M. , Group, on Behalf of Pediatric Eye Disease Investigator

Pediatrics | November 5, 2004 | Volume: 114 | Issue: 5 | Pages: 1366-1367

10.1542/peds.2004-1661 Get It

Recent Advances in the Treatment of Amblyopia
Repka, Michael X. , Quinn, Graham E. , Beck, Roy W. , Holmes, Jonathan M.

Pediatrics | August 14, 2004 | Volume: 113 | Issue: 6 | Pages: 1800-1802

10.1542/peds.113.6.1800 Get It